Bristol-Myers Squibb Company

BMY

NYSE

52.15

USD

+0.20(+0.38%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Bristol-Myers Squibb Company fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

17.56

Price/Book

5.73

Debt/Equity

275.12%

Return on Equity

34.65%

Dividend Yield

4.76%

EBITDA

3.17B

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Statements Highlights

AnnualQuarterly

Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Total Revenue	42,518,000,000	46,385,000,000	46,159,000,000	45,006,000,000	48,300,000,000
Gross Profit	21,700,000,000	26,761,000,000	26,490,000,000	25,357,000,000	27,432,000,000
Operating Income	4,492,000,000	9,540,000,000	9,271,000,000	8,472,000,000	9,658,000,000
Net Income	-8,995,000,000	6,994,000,000	6,327,000,000	8,025,000,000	-8,948,000,000
Total Assets	118,481,000,000	109,314,000,000	96,820,000,000	95,159,000,000	92,603,000,000
Total Current Liabilities	19,080,000,000	21,868,000,000	21,890,000,000	22,262,000,000	23,774,000,000
Total Equity	37,882,000,000	36,006,000,000	31,118,000,000	29,485,000,000	16,388,000,000
Free Cash Flow	13,299,000,000	15,234,000,000	11,948,000,000	12,651,000,000	13,942,000,000
Cash from Operations	14,052,000,000	16,207,000,000	13,066,000,000	13,860,000,000	15,190,000,000
Cash from Investing	-10,859,000,000	-538,000,000	-1,062,000,000	-2,295,000,000	-21,352,000,000
Cash from Financing	-1,151,000,000	-16,224,000,000	-16,962,000,000	-9,416,000,000	5,127,000,000
Net Change in Cash	2,153,000,000	-657,000,000	-4,991,000,000	2,194,000,000	-1,172,000,000

Bristol-Myers Squibb Company

BMY

52.15

Bristol-Myers Squibb Company fundamentals

Key ratios

Statements Highlights

Dividends

Analyst Recomendations